Related Experiment Video

Updated: May 10, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

AKR1C3 as a target in castrate resistant prostate cancer

Adegoke O Adeniji1, Mo Chen, Trevor M Penning

  • 1Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6061, USA.

The Journal of Steroid Biochemistry and Molecular Biology
|June 11, 2013
PubMed

Insights

Aberrant androgen receptor (AR) activation drives castrate-resistant prostate cancer (CRPC). Targeting Aldo-keto reductase 1C3 (AKR1C3), crucial for androgen biosynthesis, offers a promising therapeutic strategy for CRPC.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Aberrant androgen receptor (AR) activation is a primary driver of castrate-resistant prostate cancer (CRPC).
  • CRPC is a fatal condition necessitating novel therapeutic strategies.
  • Targeting the androgen axis, including androgen biosynthesis and AR signaling, is a key approach for CRPC treatment.

Purpose of the Study:

  • To review the critical role of Aldo-keto reductase 1C3 (AKR1C3) in prostate cancer progression.
  • To discuss recent advancements in developing selective AKR1C3 inhibitors for CRPC therapy.

Main Methods:

  • Review of scientific literature on AKR1C3 function in prostate cancer.
  • Analysis of studies investigating AKR1C3 inhibitors.

Main Results:

  • AKR1C3 catalyzes the conversion of androgen precursors to active androgens like testosterone and 5α-dihydrotestosterone.
  • AKR1C3 expression and activity are implicated in CRPC development.
  • Selective inhibition of AKR1C3 is challenging due to closely related isoforms (AKR1C1, AKR1C2).

Conclusions:

  • AKR1C3 is a rational therapeutic target for CRPC.
  • Development of potent and selective AKR1C3 inhibitors is crucial for effective CRPC treatment.
Keywords:
AndrogensNonsteroidal anti-inflammatory drugsProstaglandin F synthaseProstate cancerType 5 17β-hydroxysteroid dehydrogenase

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...